RTW Biotech Opp. - Monthly Valuation Update & Factsheet
14/03/2024 07:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240314:nRSN7819Ga&default-theme=true RNS Number : 7819G RTW Biotech Opportunities Ltd 14 March 2024 LEI: 549300Q7EXQQH6KF7Z84 14 March 2024 RTW Biotech Opportunities Ltd Monthly Valuation Update & Factsheet RTW Biotech Opportunities Ltd (the "Company" or "RTW Bio") announces that the unaudited net asset value attributable to the ordinary shares of the Company (the "NAV") at the close of business on 29 February was US$658.3m, or US$1.93 per ordinary share. The monthly factsheet is available on the Company's website: https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/ (https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/) It is important to note that the above NAV and NAV per share are unaudited and are calculated based on the following assumptions and calculations: · 341,163,649 shares were used as the denominator for the per share calculation. As per the "Completion of Acquisition" announcement published on 13 February 2024, the calculation of the denominator excludes 48,322,863 New RTW Bio Shares issued to RTW Biotech Opportunities Operating Ltd in respect of its shareholding in Arix held by the Company. · Certain Arix private assets have been valued on a preliminary basis pending implementation of the Manager's full valuation process. · The return of some additional, reasonably expected excess capital held by the Arix liquidator. For Further Information: RTW Investments, LP +44 20 7959 6361 Woody Stileman, Managing Director, Business Development ir@rtwfunds.com (mailto:ir@rtwfunds.com) Krisha McCune, Director, Investor Relations Buchanan (PR & Communications Adviser) +44 20 7466 5107 Charles Ryland Henry Wilson George Beale Deutsche Numis (Joint Corporate Broker) +44 20 7260 1000 Freddie Barnfield Nathan Brown Euan Brown BofA Securities (Joint Corporate Broker) +44 20 7628 1000 Edward Peel Alex Penney Cadarn Capital (Distribution & IR Partner) +44 73 6888 3211 David Harris Elysium Fund Management Limited +44 (0) 14 8181 0100 Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director Morgan Stanley Fund Services USA LLC +1 914 225 8885 About Biotech Opportunities Ltd: RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies. Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd (https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more information. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END UPDQKNBPDBKBBND